Loading…
Sema4 announced a definitive agreement to acquire GeneDx, a subsidiary of OPKO Health, strengthening its genomic and clinical data platform. The deal is projected to deliver $350 million in pro forma 2022 revenue, with a $200 million private placement from investors including Pfizer.